Immune Control of Conshohocken, Pennsylvania, has rounded up $11.3 million in venture capital from BioAdvance Ventures, a venture fund run by Quaker BioVentures, Domain Associates, NewSpring Capital and Anthem Capital. Immune Control says the money will fund two trials of serotonin antagonists as treatments for diseases marked by aberrant immune activation.
- read this press release for more